皓元医药 (688131)
Shanghai Haoyuan Chemexpress Co., Ltd.
K-Line Chart
No K-line data available
Company NameShanghai Haoyuan Pharmaceutical Co., Ltd.
Listing Date2021-06-08
Issue Price64.99RMB
Registered Capital21209.876510k RMB
Legal RepresentativeZheng Baofu
Registered AddressRoom 501, No. 2, Lane 720, Cailun Road, China (Shanghai) Pilot Free Trade Zone
IndustryMedical Services
Main BusinessResearch and development of molecular building blocks and tool compounds in the field of small molecule drug discovery, as well as process R&D and production technology improvement for small molecule drug active pharmaceutical ingredients (APIs) and intermediates.
Company ProfileShanghai Haoyuan Pharmaceutical Co., Ltd. was founded in 2006 and is located in the Shanghai Zhangjiang Biopharmaceutical Base. It is a high-tech enterprise specializing in the research and development of molecular building blocks and tool compounds in the field of small molecule drug discovery, as well as process R&D and production technology improvement for small molecule drug APIs and intermediates. The company provides global pharmaceutical companies and research institutions with related products and technical services ranging from drug discovery to the large-scale production of APIs and pharmaceutical intermediates. The company has been honored with numerous titles, including Shanghai's 'Specialized, Refined, Distinctive, and Innovative' Enterprise, Shanghai's Little Giant Enterprise, Shanghai's Brand Cultivation Demonstration Enterprise, and Shanghai's Patent Pilot Enterprise.
Haoyuan Pharmaceutical is deeply rooted in the biopharmaceutical field, consistently adhering to independent technological innovation and daring to tackle technical challenges. After years of technological accumulation, the company has established several core technology platforms, including a High-Potency Active Pharmaceutical Ingredient (HPAPI) Development Platform, a Vitamin D Derivative Drug API R&D Platform, a Specialty Targeted Drug Development Platform, a Drug Solid-State Chemistry Research Technology Platform, a Multi-Chiral Complex Drug Technology Platform, and a Molecular Building Block and Tool Compound Development Incubation Platform. Its service scope covers therapeutic areas such as anti-tumor, anti-viral, anti-diabetes, cardiovascular and cerebrovascular, immune system, and nervous system.
Stock Details
1. Key Indicators
- Total Shares(W): 734059.07
- Circulating A-Shares(W): 734059.07
- Earnings Per Share(RMB): 1.23
- Net Assets Per Share(RMB): 5.67
- Operating Revenue(W RMB): 1345261.60
- Total Profit(W RMB): 1345261.60
- **Net Profit Attributable to Parent(W RMB) **: 1345261.60
- Net Profit Growth Rate(%): -55.89
- Weighted Return on Equity(%): 4.6500
- Operating Cash Flow Per Share(RMB): 1.23
- Undistributed Profit Per Share(RMB): 1.23
- Capital Reserve Per Share(RMB): 1.23
2. Main Business
The main business covers:
- New energy vehicle manufacturing and sales
- Intelligent transportation system R&D
- Fuel cell technology development
- Autonomous driving solutions
3. Company Basic Information
- Company Name: Dongfeng Automobile Co., Ltd.
- Listing Date: 2001-05-18
- Industry: Automobile Manufacturing
- Address: Economic and Technological Development Zone, Wuhan City, Hubei Province
- Website: https://www.dongfeng.com.cn/
- Company Profile: The company was established with Beijing Capital Venture Group as the main sponsor....
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shanghai Anxu Information Technology Co., Ltd. | General Legal Person | 6808.29 | 32.10 |
| 2 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 860.68 | 4.06 |
| 3 | Shanghai Chenxiao Enterprise Management Consulting Center (Limited Partnership) | General Legal Person | 836.92 | 3.95 |
| 4 | China Europe Healthcare Hybrid Securities Investment Fund Class A | Fund | 725.73 | 3.42 |
| 5 | Shanghai Kangfeng Investment Management Co., Ltd. | General Legal Person | 644.83 | 3.04 |
| 6 | Shanghai Chenmai Enterprise Management Center (Limited Partnership) | General Legal Person | 548.80 | 2.59 |
| 7 | Xinyu Chengzhongtang Investment Management Center (Limited Partnership) | General Legal Person | 406.52 | 1.92 |
| 8 | Ningbo Chenxi Investment Partnership (Limited Partnership) | General Legal Person | 274.40 | 1.29 |
| 9 | China Europe Medical Innovation Equity Securities Investment Fund Class A | Fund | 220.63 | 1.04 |
| 10 | China Universal Healthcare Hybrid Securities Investment Fund | Fund | 141.03 | 0.66 |
5. Concept Sectors
- Convertible Bonds
- Artificial Intelligence
- CXO Concept
- Innovative Drugs
- Weight Loss Drugs
- Synthetic Biology
- AI Healthcare
- Margin Trading
- High-Performance Stocks
- Specialized, Refined, Unique, and New Enterprises
- SSE 380
- STAR Market Biotech
- STAR Market 200
Remarks
- Data update date: 2025-09-30
- Data source: Public market information